Browsing Cancer Therapeutics by author "Kaiser, Martin"
Now showing items 1-20 of 28
-
A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study.
Cook, G; Royle, K-L; Pawlyn, C; Hockaday, A; Shah, V; et al. (ELSEVIER SCI LTD, 2019-03-01)BACKGROUND: Tolerability of treatments for multiple myeloma can depend on the characteristics of the patient being treated. We aimed to develop and validate a risk profile, using routinely collected data, that could predict ... -
A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis.
Bødker, JS; Brøndum, RF; Schmitz, A; Schönherz, AA; Jespersen, DS; et al. (ELSEVIER, 2018-09-25)Despite the recent progress in treatment of multiple myeloma (MM), it is still an incurable malignant disease, and we are therefore in need of new risk stratification tools that can help us to understand the disease and ... -
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial.
Pawlyn, C; Cairns, D; Menzies, T; Jones, J; Jenner, M; et al. (FERRATA STORTI FOUNDATION, 2022-01-01)Autologous stem cell transplant (ASCT) remains standard of care for consolidation after induction therapy for eligible newly diagnosed myeloma patients. In recent clinical trials comparing ASCT to delayed ASCT, patients ... -
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
Jackson, GH; Pawlyn, C; Cairns, DA; de Tute, RM; Hockaday, A; et al. (PUBLIC LIBRARY SCIENCE, 2021-01-01)BACKGROUND: Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious in the treatment of myeloma and carries less risk of peripheral neuropathy than first-generation proteasome inhibitors, ... -
Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials.
Agbuduwe, C; Iqbal, G; Cairns, D; Menzies, T; Dunn, J; et al. (ELSEVIER, 2022-09-13)Immunoglobulin D (IgD) myeloma is a subtype often considered to have adverse features and inferior survival, but there is a paucity of data from large clinical studies. We compare the clinical characteristics and outcomes ... -
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.
Jones, JR; Weinhold, N; Ashby, C; Walker, BA; Wardell, C; et al. (FERRATA STORTI FOUNDATION, 2019-06-30)The emergence of treatment resistant sub-clones is a key feature of relapse in multiple myeloma. Therapeutic attempts to extend remission and prevent relapse include maximizing response and the use of maintenance therapy. ... -
Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma.
Sriskandarajah, P; De Haven Brandon, A; MacLeod, K; Carragher, NO; Kirkin, V; et al. (BMC, 2020-03-30)BACKGROUND: Multiple myeloma (MM) remains incurable despite recent therapeutic advances. RAS mutations are frequently associated with relapsed/refractory disease. Efforts to target the mitogen-activated protein kinase ... -
Detection of avascular necrosis on routine diffusion-weighted whole body MRI in patients with multiple myeloma.
Ahmed, N; Sriskandarajah, P; Burd, C; Riddell, A; Boyd, K; et al. (BRITISH INST RADIOLOGY, 2019-01-01)OBJECTIVE: Current therapies for multiple myeloma, which include corticosteroids, increase risk of avascular necrosis. The aim of this study was to assess incidental detection of femoral head avascular necrosis on routine ... -
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.
Bygrave, C; Pawlyn, C; Davies, F; Craig, Z; Cairns, D; et al. (WILEY, 2020-06-10)Predicting patient outcome in multiple myeloma remains challenging despite the availability of standard prognostic biomarkers. We investigated outcome for patients relapsing early from intensive therapy on NCRI Myeloma XI. ... -
Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial.
Coulson, AB; Royle, K-L; Pawlyn, C; Cairns, DA; Hockaday, A; et al. (BMJ PUBLISHING GROUP, 2022-06-02)INTRODUCTION: Multiple myeloma is a bone marrow cancer, which predominantly affects older people. The incidence is increasing in an ageing population.Over the last 10 years, patient outcomes have improved. However, this ... -
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
Guo, C; Chénard-Poirier, M; Roda, D; de Miguel, M; Harris, SJ; et al. (ELSEVIER SCIENCE INC, 2020-11-01)BACKGROUND: CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by ... -
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Jackson, GH; Davies, FE; Pawlyn, C; Cairns, DA; Striha, A; et al. (FERRATA STORTI FOUNDATION, 2021-07-01)The optimal way to use immunomodulatory drugs as components of induction and maintenance therapy for multiple myeloma is unresolved. We addressed this question in a large phase III randomized trial, Myeloma XI. Patients ... -
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson, GH; Davies, FE; Pawlyn, C; Cairns, DA; Striha, A; et al. (ELSEVIER SCIENCE INC, 2019-01-01)BACKGROUND: Patients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide ... -
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
de Tute, RM; Pawlyn, C; Cairns, DA; Davies, FE; Menzies, T; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-09-01)PURPOSE: Minimal residual disease (MRD) can predict outcomes in patients with multiple myeloma, but limited data are available on the prognostic impact of MRD when assessed at serial time points in the context of maintenance ... -
Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs.
Jones, JR; Barber, A; Le Bihan, Y-V; Weinhold, N; Ashby, C; et al. (SPRINGERNATURE, 2021-10-01) -
Neutral tumor evolution in myeloma is associated with poor prognosis.
Johnson, DC; Lenive, O; Mitchell, J; Jackson, G; Owen, R; et al. (AMER SOC HEMATOLOGY, 2017-10-05)Recent studies suggest that the evolutionary history of a cancer is important in forecasting clinical outlook. To gain insight into the clonal dynamics of multiple myeloma (MM) and its possible influence on patient outcomes, ... -
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Jackson, GH; Pawlyn, C; Cairns, DA; Striha, A; Collett, C; et al. (WILEY, 2021-03-01)Second-generation immunomodulatory agents, such as lenalidomide, have a more favourable side-effect profile than the first-generation thalidomide, but their optimum combination and duration for patients with newly diagnosed ... -
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial.
Panopoulou, A; Cairns, DA; Holroyd, A; Nichols, I; Cray, N; et al. (AMER SOC HEMATOLOGY, 2023-04-06)Prediction of individual patient benefit from lenalidomide (Len) maintenance after autologous stem cell transplant (ASCT) remains challenging. Here, we investigated extended molecular profiling for outcome prediction in ... -
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.
Pawlyn, C; Bright, MD; Buros, AF; Stein, CK; Walters, Z; et al. (SPRINGERNATURE, 2017-03-31)Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation. Outcomes for myeloma patients have improved over the past few decades except for molecularly ... -
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.
Davies, FE; Pawlyn, C; Usmani, SZ; San-Miguel, JF; Einsele, H; et al. (AMER ASSOC CANCER RESEARCH, 2022-07-06)The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in ...